Re: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Fingerprint Dive into the research topics of 'Re: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial'. Together they form a unique fingerprint.